Evaluation of the antidiarrheal activity of 80% methanol extract and solvent fractions of the leaf of Bersama abyssinica fresen (Melianthaceae) in mice.
Animals
Antidiarrheals
/ pharmacology
Castor Oil
Chloroform
Defecation
/ drug effects
Diarrhea
/ chemically induced
Ethiopia
Feces
Gastrointestinal Motility
/ drug effects
Intestines
/ drug effects
Magnoliopsida
Medicine, African Traditional
Methanol
Mice
Phytotherapy
Plant Extracts
/ pharmacology
Plant Leaves
Random Allocation
Solvents
Antidiarrheal
Bersama abyssinica
Castor oil
In vivo
Mice
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
06 Jan 2022
06 Jan 2022
Historique:
received:
22
09
2021
accepted:
23
12
2021
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
14
1
2022
Statut:
epublish
Résumé
The use of traditional medicinal plants in the management of diarrhea has long been practiced in Ethiopia. B. abyssinica fresen is one of the plants traditionally used to treat diarrhea whereas an in vivo study had not yet been conducted. Thus, this study aimed to evaluate the antidiarrheal activity of crude extract and solvent fractions of the leaf of B. abyssinica in mice. Cold maceration within 80% methanol was used to extract the leaf powder and extract of the leaf was fractionated using n-hexane, chloroform, and distilled water. The in vivo antidiarrheal activity of crude extracts and solvent fractions were tested in experimental models of castor oil-induced diarrhea, enteropooling, and antimotility test. Five groups each with 6 mice were used under the three antidiarrheal models. Positive controls were treated with loperamide 3 mg/kg and atropine 5 mg/kg and 2% tween 80 was used in the treatment of negative controls. The extract and solvent fractions were administered at doses of 100, 200, and 400 mg/kg. Time of onset of diarrhea, number and weight of total and wet feces, the percent reduction in the number of wet feces, weight and volume of intestinal contents, and percent inhibition of intestinal motility were recorded. Data were analyzed using SPSS version 20. Defecation of castor oil-induced diarrheal or loose stools was inhibited (p < 0.01 to p < 0.001) at 200 mg/kg and 400 mg/kg of crude extract and aqueous fraction. The crude extract and the aqueous fraction at three doses (p < 0.01 to p < 0.001), the chloroform fraction at 200 mg/kg and 400 mg/kg (p < 0.01 to p < 0.001), and the n-hexane fraction at 400 mg/kg (p < 0.05) reduced intraluminal fluid accumulation compared with the negative control. Castor oil-induced intestinal motility was significantly suppressed with the three-doses of aqueous fraction (p < 0.05 to p < 0.001), 200 mg/kg and 400 mg/kg of crude extract (p < 0.05 to p < 0.01), 400 mg/kg of chloroform and n-hexane (p < 0.01 to p < 0.001) compared with negative control. The crude extract, aqueous, and chloroform fractions of B. abyyssinica leaves have promising anti-diarrheal effects, supporting the plant's traditional use to treat diarrhea.
Identifiants
pubmed: 34991582
doi: 10.1186/s12906-021-03498-6
pii: 10.1186/s12906-021-03498-6
pmc: PMC8734363
doi:
Substances chimiques
Antidiarrheals
0
Plant Extracts
0
Solvents
0
Chloroform
7V31YC746X
Castor Oil
8001-79-4
Methanol
Y4S76JWI15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Informations de copyright
© 2022. The Author(s).
Références
Int J Environ Health Res. 2021 Apr;31(3):285-297
pubmed: 31411055
Phytother Res. 2001 Feb;15(1):62-9
pubmed: 11180526
J Pharm Pharmacol. 1978 Jan;30(1):41-5
pubmed: 22723
Antioxidants (Basel). 2020 Feb 17;9(2):
pubmed: 32079363
Evid Based Complement Alternat Med. 2018 Oct 4;2018:1360486
pubmed: 30402115
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9179-84
pubmed: 22615395
J Adv Pharm Technol Res. 2011 Jan;2(1):39-42
pubmed: 22171290
BMC Complement Altern Med. 2017 Feb 10;17(1):103
pubmed: 28183311
Evid Based Complement Alternat Med. 2020 Jan 17;2020:5416749
pubmed: 32419812
J Ethnopharmacol. 2005 Mar 21;97(3):421-7
pubmed: 15740876
Evid Based Complement Alternat Med. 2018 Feb 6;2018:3037120
pubmed: 29541140
Evid Based Complement Alternat Med. 2020 Jun 9;2020:9467359
pubmed: 32595751
J Integr Med. 2017 Mar;15(2):158-164
pubmed: 28285621
J Evid Based Integr Med. 2019 Jan-Dec;24:2515690X19833340
pubmed: 30889972
Pharm Biol. 2019 Dec;57(1):477-484
pubmed: 31438784
Pharm Biol. 2014 May;52(5):614-20
pubmed: 24392738
Asian Pac J Trop Med. 2012 Feb;5(2):147-50
pubmed: 22221760
J Evid Based Integr Med. 2020 Jan-Dec;25:2515690X20935827
pubmed: 32718177
J Evid Based Integr Med. 2019 Jan-Dec;24:2515690X19891952
pubmed: 31840545
BMC Complement Altern Med. 2014 Dec 02;14:460
pubmed: 25465058
J Pharm Pharm Sci. 2004 Feb 25;7(1):70-5
pubmed: 15144737
BMC Complement Altern Med. 2016 Aug 05;16:272
pubmed: 27492007